Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Saroglitazar is a novel medication for dyslipidemia, but its specific effects remain unclear. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of saroglitazar for managing dyslipidemia. The PubMed, Scopus, and EMBASE databases were systematically search...

Descripción completa

Detalles Bibliográficos
Autores principales: Menezes Junior, Antonio da Silva, Oliveira, Vinícius Martins Rodrigues, Oliveira, Izadora Caiado, de Sousa, André Maroccolo, Santana, Ana Júlia Prego, Carvalho, Davi Peixoto Craveiro, Paro Piai, Ricardo Figueiredo, Matos, Fernando Henrique, de Paiva, Arthur Marot, Reis, Gabriel Baêta Branquinho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488550/
https://www.ncbi.nlm.nih.gov/pubmed/37685742
http://dx.doi.org/10.3390/jcm12175674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488550/
https://www.ncbi.nlm.nih.gov/pubmed/37685742
http://dx.doi.org/10.3390/jcm12175674

Ejemplares similares